IL-23与IL-17抑制剂相对TNF抑制剂感染风险的人群研究
该全球队列研究比较银屑病患者使用IL-23i或IL-17i与TNFi的26种感染风险。经倾向评分匹配后,IL-23i和IL-17i均与多种感染风险降低相关,IL-23i关联中耳炎、脑炎、带状疱疹、HBV再激活、CMV、流感及寄生虫病风险降低,IL-17i关联肺炎、败血症、上呼吸道感染、带状疱疹、HBV/HCV再激活、CMV、EBV、流感及寄生虫病风险降低。
要点
- IL-23i相比TNFi与带状疱疹(HR 0.58)、HBV再激活(HR 0.24)、流感(HR 0.52)等风险降低相关。
- IL-17i相比TNFi与肺炎(HR 0.76)、上呼吸道感染(HR 0.84)、带状疱疹(HR 0.79)等风险降低相关。
- 对易感感染的患者,IL-23i和IL-17i可能优于TNFi。
核心结论
- 与TNFi相比,IL-23i和IL-17i与多种感染性疾病风险降低相关。
- 对感染易感性患者,这些药物可能更受青睐。
研究设计与样本
- 全球队列研究,包含两个分析:IL-23i新使用者(n=5272)对比TNFi(n=5272);IL-17i新使用者(n=15160)对比TNFi(n=15160)。
- 采用倾向评分匹配优化组间可比性,比较26种感染风险。
主要发现
- IL-23i组相比TNFi组:中耳炎HR 0.66(95%CI 0.44-0.97)、脑炎HR 0.18(95%CI 0.04-0.78)、带状疱疹HR 0.58(95%CI 0.41-0.82)、HBV再激活HR 0.24(95%CI 0.12-0.47)、CMV HR 0.25(95%CI 0.07-0.86)、流感HR 0.52(95%CI 0.38-0.71)、寄生虫病HR 0.78(95%CI 0.64-0.95)。
- IL-17i组相比TNFi组:肺炎HR 0.76(95%CI 0.68-0.85)、败血症HR 0.84(95%CI 0.72-0.97)、上呼吸道感染HR 0.84(95%CI 0.77-0.92)、带状疱疹HR 0.79(95%CI 0.67-0.92)、HBV再激活HR 0.59(95%CI 0.46-0.76)、HCV再激活HR 0.71(95%CI 0.57-0.88)、CMV HR 0.58(95%CI 0.36-0.93)、EBV HR 0.38(95%CI 0.19-0.75)、流感HR 0.70(95%CI 0.61-0.81)、寄生虫病HR 0.80(95%CI 0.72-0.88)。
临床怎么用
- 对于有感染易感性的银屑病患者,IL-23i和IL-17i可能较TNFi更优先选择。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of infections among patients with psoriasis undergoing interleukin (IL)-23 inhibitors (IL-23i) and IL-17 inhibitors (IL-17i) is yet to be exhaustively determined. OBJECTIVE: To assess the risk of infectious complications in patients with psoriasis managed by IL-23i and IL-17i with tumour necrosis factor inhibitors (TNFi) as a comparator. METHODS: A global cohort study comprised two distinct analyses comparing patients with psoriasis under different therapeutic modalities; (i) new users of IL-23i (n = 5272) versus TNFi (n = 5272) and (ii) new users of IL-17i (n = 15,160) versus TNFi (n = 15,160). Study groups were compared regarding the risk of 26 different infections. Propensity score matching was conducted to optimize between-group comparability. RESULTS: Patients under IL-23i had a lower risk of otitis media (HR, 0.66; 95% CI, 0.44-0.97), encephalitis (HR, 0.18; 95% CI, 0.04-0.78), herpes zoster (HZ; HR, 0.58; 95% CI, 0.41-0.82), hepatitis B virus (HBV) reactivation (HR, 0.24; 95% CI, 0.12-0.47), cytomegalovirus (HR, 0.25; 95% CI, 0.07-0.86), influenza (HR, 0.52; 95% CI, 0.38-0.71) and parasitic diseases (HR, 0.78; 95% CI, 0.64-0.95). IL-17i was associated with a decreased risk of pneumonia (HR, 0.76; 95% CI, 0.68-0.85), septicaemia (HR, 0.84; 95% CI, 0.72-0.97), upper respiratory tract infection (HR, 0.84; 95% CI, 0.77-0.92), HZ (HR, 0.79; 95% CI, 0.67-0.92), HBV (HR, 0.59; 95% CI, 0.46-0.76) and hepatitis C virus (HR, 0.71; 95% CI, 0.57-0.88) reactivation, cytomegalovirus (HR, 0.58; 95% CI, 0.36-0.93), Epstein-Barr virus (HR, 0.38; 95% CI, 0.19-0.75), influenza (HR, 0.70; 95% CI, 0.61-0.81) and parasitic diseases (HR, 0.80; 95% CI, 0.72-0.88). CONCLUSION: Compared with TNFi, IL-23i and IL-17i are associated with decreased risk of several infectious diseases. These agents might be preferred in patients with susceptibility to infections.
引用
- Kridin K, Zirpel H, Mruwat N, et al. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study. J Eur Acad Dermatol Venereol. 2023. PMID: 37466275. doi:10.1111/jdv.19328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。